Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial
| Autor: | Saumya Jayakumar, Chris Probert, Marc R. Bomhof, Raylene A. Reimer, Hena R. Ramay, Maitreyi Raman, Kevin P. Rioux, Pam Crotty, Jill A. Parnell |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Male medicine.medical_specialty medicine.medical_treatment Medicine (miscellaneous) Oligosaccharides 030209 endocrinology & metabolism Pilot Projects Gut flora digestive system Gastroenterology 03 medical and health sciences 0302 clinical medicine Weight loss Non-alcoholic Fatty Liver Disease Internal medicine Diabetes mellitus medicine Humans 030109 nutrition & dietetics Nutrition and Dietetics medicine.diagnostic_test biology business.industry Prebiotic Fatty liver Middle Aged medicine.disease biology.organism_classification 3. Good health Prebiotics Treatment Outcome Liver biopsy Female Steatosis medicine.symptom Steatohepatitis business |
| Zdroj: | EUROPEAN JOURNAL OF NUTRITION |
| ISSN: | 1436-6215 |
| Popis: | In obesity and diabetes the liver is highly susceptible to abnormal uptake and storage of fat. In certain individuals hepatic steatosis predisposes to the development of non-alcoholic steatohepatitis (NASH), a disease marked by hepatic inflammation and fibrosis. Although the precise pathophysiology of NASH is unknown, it is believed that the gut microbiota-liver axis influences the development of this disease. With few treatment strategies available for NASH, exploration of gut microbiota-targeted interventions is warranted. We investigated the therapeutic potential of a prebiotic supplement to improve histological parameters of NASH. In a placebo-controlled, randomized pilot trial, 14 individuals with liver-biopsy-confirmed NASH [non-alcoholic fatty liver activity score (NAS) ≥ 5] were randomized to receive oligofructose (8 g/day for 12 weeks followed by 16 g/day for 24 weeks) or isocaloric placebo for 9 months. The primary outcome measure was the change in liver biopsy NAS score and the secondary outcomes included changes in body weight, body composition, glucose tolerance, inflammatory markers, and gut microbiota. Independent of weight loss, oligofructose improved liver steatosis relative to placebo and improved overall NAS score (P = 0.016). Bifidobacterium was enhanced by oligofructose, whereas bacteria within Clostridium cluster XI and I were reduced with oligofructose (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink